Related Experiment Video

Updated: Jun 6, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target

F De Vita1, F Giuliani, N Silvestris

  • 1Division of Medical Oncology, F. Magrassi & A. Lanzara Department of Clinical and Experimental Medicine and Surgery, Second University of Naples School of Medicine, c/o II Policlinico, Via S. Pansini 5, Naples, Italy. fernandodevita@yahoo.it

Cancer Treatment Reviews
|December 7, 2010
PubMed

Insights

Adding trastuzumab to chemotherapy significantly improves survival for patients with HER2-positive advanced gastric cancer. This targeted therapy offers a new standard of care, improving outcomes beyond traditional chemotherapy.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Gastric cancer treatment, especially in the metastatic setting, faces challenges with limited efficacy and toxicity of current options.
  • Existing chemotherapy regimens (fluoropyrimidine, taxanes, platinum) show modest response rates (30-50%) and median survival of about one year.
  • There is a critical need for novel therapeutic strategies, particularly targeted drugs, to improve patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of adding trastuzumab to standard chemotherapy in patients with HER2-positive advanced gastric cancer.
  • To establish a new reference treatment for HER2-positive metastatic gastric cancer.

Main Methods:

  • The study involved evaluating trastuzumab in combination with chemotherapy (cisplatin and fluoropyrimidine).
  • The ToGA trial was the first to assess this combination in HER2-positive advanced gastric cancer patients.
  • Efficacy and safety data were collected and analyzed.

Main Results:

  • The combination of trastuzumab with chemotherapy demonstrated significant superiority over chemotherapy alone.
  • Trastuzumab, a monoclonal antibody targeting HER2, showed survival benefits.
  • The treatment regimen was found to be a new reference treatment for HER2-positive metastatic gastric cancer.

Conclusions:

  • Adding trastuzumab to cisplatin and fluoropyrimidine chemotherapy is a superior treatment strategy for HER2-positive advanced gastric cancer.
  • Trastuzumab represents a significant advancement in targeted therapy for this patient population.
  • This combination therapy offers improved survival and a new standard of care.

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...